Merck KGaA (MRK) Given a €100.00 Price Target at Oddo Bhf

Oddo Bhf set a €100.00 ($116.28) price objective on Merck KGaA (FRA:MRK) in a research note released on Wednesday morning. The firm currently has a neutral rating on the healthcare company’s stock.

Several other analysts have also commented on MRK. Berenberg Bank set a €104.00 ($120.93) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Thursday, August 9th. Societe Generale set a €92.00 ($106.98) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Friday, August 10th. Commerzbank set a €100.00 ($116.28) price target on shares of Merck KGaA and gave the company a buy rating in a research report on Wednesday. DZ Bank reiterated a neutral rating on shares of Merck KGaA in a research report on Monday, July 23rd. Finally, JPMorgan Chase & Co. set a €90.00 ($104.65) price target on shares of Merck KGaA and gave the company a neutral rating in a research report on Wednesday. Two equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of Hold and a consensus price target of €98.00 ($113.95).

MRK stock opened at €97.64 ($113.53) on Wednesday. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien, a science and technology company, operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: Risk Tolerance

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply